Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study by Bitossi, Alice et al.
Research Article
Adalimumab Accounts for Long-Term Control of Noninfectious
Uveitis Also in the Absence of Concomitant DMARD Treatment:
A Multicenter Retrospective Study
Alice Bitossi,1 Alessandra Bettiol,2 Elena Silvestri,3 Gerardo Di Scala,3 Daniela Bacherini,1
Giuseppe Lopalco ,4 Vincenzo Venerito,4 Florenzo Iannone,4 Antonio Vitale ,5
Gian Marco Tosi ,6 Domenico Prisco,3 Stanislao Rizzo,1 Claudia Fabiani ,5
Luca Cantarini ,5 Gianni Virgili,1 Lorenzo Vannozzi,1 and Giacomo Emmi 3
1Department of Surgery and Translational Medicine, Eye Clinic, University of Firenze, 50134, Italy
2Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, 50139, Italy
3Department of Experimental and Clinical Medicine, University of Firenze, 50134, Italy
4Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), University of Bari, 70121, Italy
5Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative
Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, 53100, Italy
6Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Siena 53100, Italy
Correspondence should be addressed to Giacomo Emmi; giacomo.emmi@unifi.it
Received 9 November 2018; Accepted 1 January 2019; Published 10 February 2019
Academic Editor: Settimio Rossi
Copyright © 2019 Alice Bitossi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. This study was aimed at assessing the long-term ocular control of adalimumab (ADA) in a large real-world population
with noninfectious primary or secondary uveitis, focusing on the steroid-sparing effect and on disease-modifying antirheumatic
drug (DMARD) cotreatment. Methods. In this retrospective, multicenter study, the efficacy of ADA was evaluated in terms of
ocular control, changes in best-corrected visual acuity (BCVA), corticosteroid-sparing effect, and drug retention rate, overall and
stratified according to DMARD cotreatment. Results. 106 patients were included. 88.7% had an associated systemic disease.
After 6 and 12 months, proportions of patients with effective ocular control were 83.7% and 83.3%, respectively. At last the
follow-up, 94.6% of patients had satisfactory ocular control. No difference in terms of ocular control at all time points emerged
among patients starting ADA for ocular vs. systemic involvements. Patients with poor baseline BCVA remained stable or
improved, while those with good BCVA hardly worsened. At 6 and 12 months, the median dose of prednisone significantly
reduced to 5mg/day (0-5) and 2.5mg/day (0-5) (p < 0 001). Over a median follow-up of 36 months, 38 subjects discontinued
ADA treatment. Mild to moderate side effects were reported in 7 patients (6.6%). ADA ocular control, corticosteroid-sparing
effect, and drug retention rate were not influenced by the concomitant use of DMARDs. Conclusion. The long-term ocular
control of ADA in noninfectious primary or secondary uveitis is confirmed, also for BCVA preservation. Concomitant use of
DMARDs does not provide additional benefits to ADA alone in terms of ocular control, steroid spare, and drug retention rate.
1. Introduction
Noninfectious primary or secondary uveitis is a group of
vision-threatening diseases characterized by intraocular
inflammation. It can occur as an isolated involvement of
the eyes or associated with a systemic condition, including
Behçet’s syndrome (BS), juvenile idiopathic arthritis (JIA),
rheumatoid arthritis (RA), Vogt-Koyanagi-Harada (VKH),
sarcoidosis (SAR), ankylosing spondylitis (AS), psoriatic
arthritis (PsA), inflammatory bowel disease (IBD), and
multiple sclerosis [1, 2].
In the developed world, uveitis accounts for an estimated
10 to 15% of the cases of total blindness and up to 20% of
legal blindness [1–3]. Uveitis can affect people of any age,
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but it most commonly develops in people between the ages of
20 and 59 years and is a major cause of visual morbidity in
the working age group [2].
Corticosteroids are still the mainstay of treatment [1].
However, long-term use of moderate to high doses of cortico-
steroids can result in serious adverse events, including both
ocular morbidity, such as glaucoma and cataract, and sys-
temic adverse events, including impaired glucose tolerance,
hypertension, osteoporosis, and infection susceptibility [2].
Other therapeutic options for noninfectious primary or
secondary uveitis comprised traditional immunosuppres-
sants (disease-modifying antirheumatic drugs (DMARDs)),
such as cyclosporine (CsA), methotrexate (MTX), azathio-
prine (AZA), sulfasalazine (SSZ), and mycophenolate mofetil
(MMF). However, a significant proportion of cases of uveitis
cannot be controlled [4].
Thus, in recent years, there has been a great interest in
identifying more effective, corticosteroid-sparing therapies,
ideally targeting specific mediators of the immune response
[5]. The proinflammatory cytokine tumor necrosis factor α
(TNF-α) is thought to play a key role in uveitis inflammation,
and aqueous humor and serum levels of TNF-α are upregu-
lated in patients with uveitis [1–4, 6].
Adalimumab (ADA), a recombinant human immuno-
globulin (IgG1) monoclonal antibody that specifically binds
to TNF-α [2, 7, 8], is the only systemic noncorticosteroid
agent currently approved for the treatment of noninfectious
primary or secondary uveitis [9].
Indeed, two phase 3 clinical trials, VISUAL-1 and
VISUAL-2, have been conducted among patients with active
and inactive uveitis, respectively. In both trials, ADA led to a
significant and clinical improvement in visual functioning
[1, 8]. Furthermore, in the phase 3, open-label, extension
trial VISUAL-III, ADA proved effective in inducing quies-
cence, improving best-corrected visual acuity (BCVA), and
reducing the daily uveitis-related systemic steroid use, with
poor safety concerns [10].
Nevertheless, a large proportion of subjects included in
these trials had idiopathic uveitis, in the absence of systemic
inflammatory disorders. Thus, the replicability of these
results, and in particular of the steroid-sparing potential
of ADA, in patients with uveitis secondary to a systemic
disease, is still a matter of debate. What is more, the real
contribution of DMARDs in the response to and drug
retention rate on ADA treatment, particularly in secondary
uveitis, is still unclear. Furthermore, only a small number of
studies have evaluated ADA efficacy for the treatment of
noninfectious primary or secondary uveitis in a real-world
setting [11–13].
In light of these considerations, our primary objective
was to assess the long-term ocular control of ADA in a
large and heterogeneous real-world population with nonin-
fectious primary or secondary uveitis. The secondary objec-
tives of the study were the evaluation of ADA effectiveness
in inducing changes in the BCVA and variations in cortico-
steroid use, the ADA retention rate and its safety profile,
and the assessment of the impact of concomitant DMARD
treatment on ocular response, steroid variations, and drug
retention rate.
2. Materials and Methods
2.1. Study Setting and Population. A retrospective, observa-
tional, multicenter study was conducted based on medical
chart review of 3 Italian tertiary referral centers (Firenze,
Siena, and Bari). Ocular data recorded in the medical chart
derived from either ambulatory ocular visits alone or associ-
ation to a concomitant angiography, autofluorescence, or
optic coherence tomography (OCT) examination.
All adult patientswithnoninfectiousprimaryor secondary
uveitis (anterior, intermediate, posterior uveitis, panuveitis or
scleritis, idiopathic or secondary to a systemic disease, treated
with ADA standard dose (40mg/every 2 weeks subcutane-
ously)) were included.
We collected data on demographic information, systemic
diagnosis (BS, JIA, PsA, AS, and IBD), type of ocular involve-
ment, and previous or ongoing immune-modulating
treatment.
We defined ocular flare as the presence of anterior cham-
ber cells of 1+ (or higher) or vitreous haze of 1+ (or more) or
active chorioretinal lesions, inflammatory retinal vascular
lesions, or optic nerve inflammation, or by medical chart
reviews, as previously described [12]. For patients with scler-
itis, ocular flare was defined as the presence of scleral inflam-
mation of 1+ (or higher) or clinical and ultrasonographic
findings as previously described [14, 15].
Evaluation was performed per patient and not per eye.
When both eyes were affected, the worse eye was evaluated.
For each patient, clinical data were collected at the
time of the first ADA administration, at 6 and 12 months
following ADA beginning and at time of the last follow-up
visit. No exclusion criterion was applied to follow-up, i.e.,
patients not reaching the 6 months of follow-up were not
excluded from the study, thus including in the study the
whole cohort of patients treated with adalimumab in our
real clinical practice.
2.2. Outcomes. The primary endpoint was ADA ocular
control at 6 and 12 months and at last available
follow-up. Ocular control was defined as follows: absence of
ocular flare in both eyes and reduction of the daily predni-
sone (or prednisone-equivalent) dose to ≤10mg/day or
halving of the initial steroid dose.
Secondary outcomes included (i) changes in BCVA, (ii)
variations in corticosteroids’ daily dose, (iii) drug retention
rate, (iv) occurrence of any adverse event, and (v) impact of
concomitant DMARD treatment on ocular response, steroid
variations, and drug retention rate.
As for BCVA, subjects were categorized into three
groups, based on the BCVA of the worst eye: VA ≤20/200,
>20/200-≤20/40, and >20/40 (Snellen chart). Variations in
VA were defined as the proportion of subjects that changed
VA group from baseline to final evaluation.
As for DMARD cotreatment, subjects were categorized in
the “ADA+DMARD” group, if both ADA and DMARDs
were administered during the entire first year of available
follow-up, and the “only ADA” group, if DMARDs were
never administered during the entire first year of available
follow-up. Subjects cotreated with DMARDs only for a
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certain period during follow-up were excluded from
this analysis.
2.3. Statistical Analysis. Descriptive statistics was used to
describe the demographic and clinical characteristics of
the included subjects. Continuous variables were reported
as median values and relative interquartile ranges (IQR)
and were compared using the Kruskal-Wallis test. Categorical
variables were reported as absolute frequencies and percent-
ages andwere compared using the Fisher exact test.Univariate
Cox regressionmodel was used to derive Kaplan-Meier curves
for drug retention rate on treatment. Statistical analysis was
performed using the Stata software version 14. Statistical
significance was considered for p values< 0.05.
3. Results
3.1. Characteristics of Patients and Treatments. One hundred
and six patients treated with ADA for noninfectious primary
or secondary uveitis were included. Median age (IQR) at
onset of uveitis was 29 years (20.5-40); fifty-nine patients
(55.66%) were female. Median follow-up was 36.02 months
(16.27-59.17). Clinical characteristics of the cohort are
summarized in Table 1.
Fifty-one patients (48.11%) had intermediate uveitis
associated with either posterior or panuveitis, 45 (42.45%)
had anterior uveitis, and 10 (9.43%) had scleritis (alone or
with uveitis); 64 patients (60.38%) had bilateral uveitis.
As for systemic involvement, the great majority of
patients (94; 88.68%) had an associated systemic disease,
whereas twelve patients had idiopathic uveitis (11.32%).
The most common associated systemic conditions were BS
(66, 62.26%), followed by JIA, PsA, AS, and IBD, which have
been included in a single group named “other” (28, 26.42%:
11 JIA, 5 PsA, 11 AS, and 1 IBD).
76 patients began ADA for the treatment of the ocular
involvement (associated with systemic manifestations in 49
of them), whereas 30 patients started ADA for the systemic
manifestations, although all of them had history of ocular
involvement. Specifically, 12 patients had ocular manifesta-
tions in the year before ADA beginning (of them, 3 patients
had more than one ocular flare in the same year); the remain-
ing 18 patients had history of ocular involvements but had no
ocular flare in the year before ADA beginning.
Specifically, out of the 49 subjects with both ocular and
systemic involvements at the time of ADA beginning, 30
had BS, 8 had JIA, 8 had AS, and 3 had PsA. As for the 30
patients that started ADA for systemic manifestations, 21
had BS, 4 had JIA, 2 had PsA, 2 had AS, and 1 had IBD.
Before ADA beginning, 59 patients (55.66%) were treated
with synthetic DMARDs, 7 (6.60%) with other biologics, 23
(21.70%) with both synthetic and biologic DMARDs, and 17
(16.04%) did not receive any systemic immune-modulating
treatment. As for biologics, 17 patients had been treated
with infliximab, 4 with etanercept, 2 with anakinra, 1 with
rituximab, 1 with certolizumab, and 5 with more than one
drug. As for DMARDs, 21 patients had been treated with
CsA, 21 with MTX, 16 with AZA, 2 with SSZ, and 24 with
more than one drug.
Otherwise, at the beginning of ADA treatment, 53
patients (50.00%) were treated with synthetic DMARDs, 7
(6.60%) with biologics, and 4 (3.77%) with both, whereas
31 patients (29.25%) were off-treatment.
As for biologics, 8 patients were treated with infliximab, 1
with etanercept, 1 with anakinra, and 1 with rituximab. As
for DMARDs, 15 were treated with CsA, 23 with MTX, 17
with AZA, 1 with SSZ, and 1 with MMF.
3.2. Primary Endpoint: Ocular Control. Table 2 shows the
ocular outcomes of ADA therapy over time, in terms of over-
all ocular control. Due to the variability in treatment length
Table 1: Baseline demographic and clinical characteristics.
Characteristics
n (% out of 106)
Sex
Men 47 (44.34)
Women 59 (55.66)
Median age (IQR) at onset of uveitis, years
29.00
(20.50-40.00)
Associated disease
No (idiopathic uveitis) 12 (11.32)
Yes 94 (88.68)
Behçet syndrome 66 (62.26)
Other (JIA, PsA, AS, VKH, and IBD) 28 (26.42)
Median follow-up, months
36.02
(16.27-59.17)
Median duration of uveitis at ADA beginning
(IQR), years
4.00
(1.00-11.00)
Type of uveitis
Anterior 45 (42.45)
Posterior and/or panuveitis (and/or
intermediate)
51 (48.11)
Unilateral 42 (39.62)
Bilateral 64 (60.38)
Previous treatment
None 17 (16.04)
Only synthetic DMARDs 59 (55.66)
Only biologics 7 (6.60)
Synthetic DMARDs and biologics 23 (21.70)
Baseline treatment
None 31 (29.25)
Only synthetic DMARDs 53 (50.00)
Only biologics 7 (6.60)
Synthetic DMARDs and biologics 4 (3.77)
Missing 11 (10.38)
Ocular flare
In the 12 months before ADA treatment 76 (71.70)
At baseline 70 (66.04)
ADA: adalimumab; AS: ankylosing spondylitis; DMARDs: disease-modifying
antirheumatic drugs; IBD: intestinal bowel disease; JIA: juvenile idiopathic
arthritis; PsA: psoriatic arthritis; VKH: Vogt-Koyanagi-Harada.
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and to losses at follow-up, the number of observed patients
decreased over time from 106 at baseline to 92 at 6 months
and to 78 at 12 months.
Within 6 months of ADA treatment, ocular control,
defined as reported in Materials and Methods, was achieved
in 77 out of 92 patients (83.7%). Specifically, proportions of
ocular control at 6 months were 83.1% among patients start-
ing ADA for the ocular involvement (alone or with concom-
itant systemic manifestations; n = 54 out of 65) and 85.2%
among patients starting ADA for the systemic involvement
(n = 23 out of 27) (p = 1 000).
The proportion of subjects achieving ocular control was
maintained at 12 months of treatment (65 out of 78 subjects;
83.3%). Specifically, proportions of ocular control at 12
months were 80.4% among patients starting ADA for the
ocular involvement (n = 45 out of 56) and 90.9% among
patients starting ADA for the systemic involvement (n = 23
out of 27) (p = 0 330).
Among the 55 patients with an available follow-up lon-
ger than 12 months (median follow-up was 36.02 months),
this percentage further increased to 94.5%. Of note, pro-
portions of ocular control among patients with an avail-
able follow-up longer than 12 months were 91.7% in
patients with ocular involvement and 100.0% among
patients with only systemic involvement at the time of
ADA beginning.
Notably, 18 patients had macular edema (ME) at baseline
(16.98%). Among them, ME resolved in 14 (77.78%) patients.
Of note, in one patient diagnosed with scleritis, ME devel-
oped during ADA treatment.
Table 2: Ocular control of adalimumab (ADA) therapy, overall and stratified according to the concomitant use of DMARDs.
Observed 6 months 12 months >12 months
Overall, N (%)
N. obs. 106 92 78 55
Ocular control — 77 (83.7) 65 (83.3) 52 (94.6)
No ocular control — 15 (16.3) 13 (16.7) 3 (5.5)
Stratified according to reason for ADA beginning:
Ocular (+/- systemic)
N. obs. 76 65 56 36
Ocular control — 54 (83.1) 45 (80.4) 33 (91.7)
Systemic
N. observed 30 27 27 19
Ocular control — 23 (85.2) 23 (90.9) 19 (100.0)
Stratified according to DMARD cotreatment in the first year:
Only ADA group, N (%)
N. obs. 29 25 20 18
Ocular control 22 (88.0) 17 (85.0) 17 (94.4)
ADA+DMARD group, N (%)
N. obs. 29 29 25 13
Ocular control 21 (72.4) 19 (76.0) 13 (100.0)
p value∗ 0.191 0.709 n.c.
∗p value from the comparison of proportions of ocular control in the “only ADA” vs. “ADA+DMARD” groups; ADA: adalimumab; DMARDs:
disease-modifying antirheumatic drugs; n.c.: not calculable.
1
.75
.5
.25
0
≤ 20/200
> 20/200 - ≤ 20/40
> 20/40
≤ 20/200
> 20/200-≤20/40
> 20/40
Baseline VA category
35
5
7 5
1
1
2
1
Fi
na
l V
A
 ca
te
go
ry
Figure 1: Changes in visual acuity. VA: visual acuity.
4 Mediators of Inflammation
During ADA treatment, eight patients required periocu-
lar steroid injections.
3.3. Secondary Endpoints
3.3.1. Changes in Visual Acuity. Data on VA were available
for 60 subjects. Figure 1 shows changes in VA, from baseline
to final evaluation. At baseline, 11 subjects (18.33%) were
included in the lowest VA category (≤20/200), 11 (18.33%)
in the intermediate category (>20/200-≤20/40), and 38
(63.33%) in the highest category (>20/40).
Among subjects in the lowest category, 7 remained
stable whereas 4 improved (with one patient improving
to >20/40). Among subjects in the intermediate category,
5 preserved their VA and improvement to >20/40 occurred
in another 5 cases; only 1 subject worsened to ≤20/200, due
to the onset of cataract. Among the 38 subjects with the high-
est VA, 35 remained stable, whereas 3 subjects worsened and
one of them decreased VA to ≤20/200. In two of these
patients, worsening was related to the onset of cataract; the
patient that worsened to VA ≤20/200 had scleritis and devel-
oped ME during ADA treatment.
3.3.2. Corticosteroid-Sparing Effect. The variation of cortico-
steroid dosage during ADA treatment is reported in
Figure 2. Median prednisone dose at the time of ADA begin-
ning was 10 (7.5-20) mg/day. At 6 months, median dose of
prednisone was significantly reduced to 5 (0-5) mg/day
(p < 0 001). At 12 months, the dosage further decreased to
2.5 (0-5) mg/day (p < 0 001), and for patients with a
follow-up longer than 12 months, the median prednisone
dose at last follow-up was 0 (0-5).
3.3.3. Drug Retention Rate on Adalimumab Treatment.
Figure 3 shows the drug retention rate on ADA treatment.
Over the total available follow-up, 38 subjects discontinued
ADA. Rate of discontinuation was 0.15 per person-year
(0.11–0.21). Most frequent reasons for discontinuation
were inefficacy (n = 12), followed by loss of efficacy
(n = 10), side effects (n = 7), ocular remission (n = 4), and
pregnancy (n = 1).
3.3.4. Safety. Seven patients had mild to moderate side effects.
In detail, one case reported recurrent infections, one back
eczema, one vertigo, and one pneumonia, whereas in the
remaining 3 cases, the exact adverse effect was not specified.
All seven side effects required treatment discontinuation.
3.3.5. Impact of DMARD Cotreatment on Ocular Response,
Corticosteroid Spare, and Drug Retention Rate on
Adalimumab Treatment. Based on the use of DMARDs dur-
ing the first year of follow-up, 29 subjects were classified as
belonging to the “ADA+DMARD” group and the other 29
subjects to the “only ADA” group. The remaining 48 patients
were cotreated with DMARDs only for a certain period dur-
ing the first year of ADA follow-up and were therefore
excluded from this analysis.
The “only ADA” and “ADA+DMARD” groups were
comparable in terms of baseline ocular inflammation: specif-
ically, the proportion of patients with ocular flare in the 12
months before ADA beginning was 79.31% vs. 75.86%
(p = 1 000). Furthermore, the two groups were comparable
in terms of type of ocular involvements (anterior uveitis
was present in 55.16 vs. 34.48%; intermediate uveitis associ-
ated with either posterior or panuveitis in 34.48% vs.
62.07%; scleritis in 10.34% vs. 3.45%; p = 0 118). ME was
present in 4 vs. 9 patients (13.79% vs. 31.03%, p = 0 231).
As for ocular control, no difference emerged among the
two groups (Table 2). In particular, at 6 months of follow-up,
percentages of ocular control in the “only ADA” and “ADA
+DMARD” groups were 88.00% (22 out of 25) and 72.41%
(21 out of 29), respectively (p = 0 191). At 12 months, this
percentage was 85.00% (17 out of 20) and 76.00% (19 out
of 25) in the two groups, respectively (p = 0 709). At the last
follow-up, ocular control was achieved in 94.44% (17 out of
18) and 100% (13) of subjects.
Considering corticosteroid spare, a significant reduction
in median corticosteroid dose was found both in patients
Baseline 6 months 12 months > 12 months
p < 0.001
p < 0.001
p < 0.001
m
g/
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Figure 2: Variations of corticosteroid dosage over time.
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with ADA monotherapy and in patients with concomi-
tant DMARD treatment (data not shown). In particular,
the median baseline dose of corticosteroids was 12.50
(10-25) mg/day and 6.25 (2.5–15.00) mg/day in the “only
ADA” and “ADA+DMARD” groups. At 6 months, the
median dose of corticosteroids decreased to 5 (2.5-5) mg/day
(p < 0 0001) and 5 (0–7.5) mg/day (p = 0 004) in the two
groups, respectively. At 12 months and at last follow-up
(>12 months), the median dose further decreased to 0
(0-5) mg/day (p < 0 0001) and 2.5 (0–5) mg/day (p = 0 003)
in the “only ADA” and “ADA+DMARD” groups.
Focusing on the time of ADA treatment, drug retention
rate was more lasting for subjects in the “ADA+DMARD”
group (HR of discontinuing ADA treatment of 0.81
Kaplan-Meier survival estimate
1.00
0.75
0.50
0.25
0.00
0
Number at risk
106 (16) 78 (10) 50 (4) 39 (3)
12 24 36
Follow-up (months)
48 60
22 (2) 15
(a)
Kaplan-Meier survival estimates
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0.50
0.25
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0
29 20
2529
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7
7 5
2311(3)(2)
(2) (2)
(0)
(0)
(0)(1)
Only DMARDS
ADA + DMARDS
Only ADA
ADA + DMARDS
12 24 48 6036
Follow-up (months)
(b)
Figure 3: Drug retention rate on adalimumab treatment, overall (upper box) and stratified according to concomitant use of DMARDs vs.
adalimumab in monotherapy (lower box). ADA: adalimumab; DMARDs: disease-modifying antirheumatic drugs.
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(0.30-2.18) for the ADA+DMARDs vs. only ADA group),
although the difference was not statistically significant
(p = 0 682) (Figure 3).
4. Discussion
In this retrospective, multicenter real-life study, we con-
firmed the ocular control of ADA in a large and heteroge-
neous cohort of patients with noninfectious primary or
secondary uveitis. Compared with other retrospective stud-
ies, our work included a considerably larger cohort of cases.
In particular, Dobner et al. [11] evaluated ADA treatment
in 60 patients, Durrani et al. [12] in 32 patients, and Lee
et al. [13] in 22 patients. Studies with a larger population were
the trials [1, 8], but as compared to the VISUAL-1 and 2
populations, our cohort was mainly composed of subjects
with a concomitant systemic inflammatory disorder.
Thus, our results add further evidence on the ocular effi-
cacy of ADA, also in subjects with uveitis secondary to other
systemic inflammatory diseases.
Notably, our study showed that ADA is effective also in
the long-term follow-up, with more than 90% of the patients
with ocular control over a median follow-up of 36 months.
Our findings on the long-term ADA control is of importance
for clinicians, considering that all other studies had a signifi-
cantly shorter follow-up [1, 6, 8, 11–13, 16].
Moreover, we observed that patients with low VA at
baseline remained stable or improved during ADA treat-
ment, while those with good VA at the start of treatment
hardly got worse. A clear description of the final VA based
on the different VA at baseline (low, intermediate, and high)
was not reported in previous studies. Indeed, at 6 months of
follow-up, Durrani et al. [12] showed a VA improvement of
at least 20/50 or better in 23% of patients and of 20/200 or
better in 60%, while mean VA negligibly decreased. Also in
Díaz-Llopis et al.’s study [6], there was an improvement of
VA in 21.3% of the patients, stability in 75.4%, and a worsen-
ing in 3.3%. These results were partially confirmed by
Sheppard et al. [2] in the VISUA1-2 post hoc analysis, sug-
gesting that ADA is associated with a significant improve-
ment of visual functioning in patients with noninfectious
uveitis. Our data suggest that the use of ADA should not
be limited only to patients with a good VA at the begin-
ning of the treatment but also in those with a more severe
VA impairment.
Our study confirmed the corticosteroid-sparing effect of
ADA, as reported in registration trials [1, 8] and in retrospec-
tive [11–13, 17] and prospective studies [6, 18]. In addition,
our data provide additional information on the ability of
ADA to reduce prednisone dosage also in the long-term fol-
low-up, thus reducing the exposure to corticosteroids and
their side effects in the long term.
Notably, our study showed a good drug retention rate on
ADA treatment, as well as a good safety profile. In our study,
only 7 patients had side effects requiring treatment interrup-
tion. No severe side effects were observed in this large series,
in line with both retrospective studies and clinical trials [1, 8].
Of particular relevance, we found that our results on
ADA ocular control and on corticosteroid-sparing effect
were not influenced by the concomitant use of DMARDs
during the first year of follow-up. Similarly, there was no dif-
ference in the time of treatment among patients receiving
ADA alone or in association with DMARDs. Unlike other
inflammatory diseases such as rheumatoid arthritis [18, 19]
or juvenile rheumatoid arthritis [20, 21], in uveitis, ADA sur-
vival did not appear to be influenced by the concomitant use
of DMARDs. These results support and parallel those of
Cordero-Coma et al. [22]. Indeed, they did not find any pro-
tective effect of concomitant immunosuppression in the for-
mation of anti-ADA antibodies and any difference in the
time of treatment in patients with noninfectious primary or
secondary uveitis treated with ADA. Our data could be influ-
enced by the quite high number of BS patients among the
subjects of our cohort. Indeed, it has already been shown that
the time of treatment of ADA is not affected by adding
DMARDs in BS patients [23–25]. Notably, these data suggest
that adding DMARDs in noninfectious primary or secondary
uveitis does not seem useful to reach a longer time of
treatment [26–29].
The main limitation of this study is certainly its retro-
spective nature. However, to date, it is one of the largest stud-
ies on the efficacy of ADA for the treatment of noninfectious
primary or secondary uveitis in a real-life setting, with a
long-term follow-up, and the only one comparing ADA
monotherapy vs. ADA associated with DMARDs.
5. Conclusions
Our results showed the long-term effective control of ADA
also as monotherapy in patients with noninfective uveitis,
either primary or secondary to systemic disorders. Based on
our results, ADA can be effectively used in subjects with
low VA since it proved to effectively preserve or even
improve VA. Moreover, our findings suggest that the con-
comitant use of DMARDs does not seem to provide any
additional benefit to ADA alone in terms of ocular control,
reduction of steroid dose, and time of treatment.
These data add important suggestions to clinicians for
the daily management of patients with noninfectious primary
or secondary uveitis in the real-world setting.
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